Get the Stockscreener App
6.41
0.00%
0.00
Relmada Therapeutics Inc stock is traded at $6.41, with a volume of 417.11K.
It is up +0.00% in the last 24 hours and up +2.23% over the past month.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
See More
Previous Close:
$6.41
Open:
$6.38
24h Volume:
417.11K
Relative Volume:
0.27
Market Cap:
$676.75M
Revenue:
-
Net Income/Loss:
$-58.88M
P/E Ratio:
-5.7623
EPS:
-1.1124
Net Cash Flow:
$-42.79M
1W Performance:
+2.07%
1M Performance:
+2.23%
6M Performance:
+48.72%
1Y Performance:
+946.87%
1-Day Range:
$6.38
$6.61
1-Week Range:
$6.04
$6.665
52-Week Range:
$0.55
$8.00
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Name
Relmada Therapeutics Inc
Sector
Industry
Phone
646 876 3459
Address
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Compare RLMD vs MOBBW, GOODO, PSNYW, SHMD, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.09 | 3.30B | 0 | 0 | 0 | 0.00 |
GOODO
Gladstone Commercial Corporation
|
20.04 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.315 | 318.79M | 2.07B | -1.42B | -1.37B | -0.6765 |
SHMD
Schmid Group N V
|
4.97 | 327.72M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
47.15 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Initiated | Piper Sandler | Overweight |
| Jan-23-26 | Resumed | Leerink Partners | Outperform |
| Dec-22-25 | Initiated | Jefferies | Buy |
| Nov-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-05-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-17-24 | Upgrade | Jefferies | Hold → Buy |
| Jun-05-24 | Downgrade | Goldman | Neutral → Sell |
| Oct-14-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-14-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-14-22 | Downgrade | Truist | Buy → Hold |
| Oct-13-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-18-21 | Initiated | Mizuho | Buy |
| May-20-21 | Resumed | Goldman | Buy |
| Oct-28-20 | Downgrade | Goldman | Buy → Neutral |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-04-20 | Initiated | SunTrust | Buy |
| Apr-21-20 | Initiated | Goldman | Buy |
| Jan-27-20 | Initiated | Jefferies | Buy |
| Jan-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-16-19 | Initiated | Guggenheim | Buy |
View All
Relmada Therapeutics Inc Stock (RLMD) Latest News
Relmada's cancer drug candidate sparks fresh bullish call - MSN
RLMDRelmada Therapeutics Inc Options - Finviz
RELMADA THERAPEUTICS INC (RLMD) Stock Chart - ChartMill
Enterprise value to EBITDA forward of Relmada Therapeutics, Inc. – NASDAQ:RLMD - TradingView
Enterprise value to revenue forward of Relmada Therapeutics, Inc. – NASDAQ:RLMD - TradingView
Price to book forward of Relmada Therapeutics, Inc. – NASDAQ:RLMD - TradingView
Relmada Therapeutics, Inc.(NasdaqCM:RLMD) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Relmada Therapeutics, Inc.(NasdaqCM: RLMD) added to Russell 2500 Growth Benchmark - marketscreener.com
Relmada Therapeutics Joins Russell 2000, Russell 3000 Indexes - marketscreener.com
Relmada Therapeutics, Inc.(NasdaqCM: RLMD) added to Russell 2000 Index - marketscreener.com
Relmada Therapeutics added to Russell 2000 and 3000 indexes - Investing.com
Relmada Therapeutics added to Russell 2000 and 3000 indexes By Investing.com - Investing.com Australia
Relmada Therapeutics (RLMD) Joins Russell 2000 and 3000 Indices - GuruFocus
Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes - GlobeNewswire
Relmada Therapeutics, Inc.(NasdaqCM: RLMD) added to Russell 2000 Growth Benchmark - marketscreener.com
Price to earnings forward of Relmada Therapeutics, Inc. – NASDAQ:RLMD - TradingView
Relmada lands in Russell 2000 and Russell 3000 after reconstitution - Stock Titan
Relmada Therapeutics, Inc.(NasdaqCM: RLMD) added to Russell 3000E Index - marketscreener.com
Price to sales forward of Relmada Therapeutics, Inc. – NASDAQ:RLMD - TradingView
Relmada Therapeutics, Inc.(NasdaqCM: RLMD) added to Russell Microcap Index - marketscreener.com
Relmada Therapeutics, Inc.(NasdaqCM: RLMD) added to Russell 3000 Index - marketscreener.com
Relmada Therapeutics, Inc.(NasdaqCM: RLMD) added to Russell 2500 Index - marketscreener.com
RLMD Jumps As HC Wainwright Launches Buy Coverage - timothysykes.com
RLMD Jumps As H.C. Wainwright Launches Bullish Coverage - timothysykes.com
Relmada Therapeutics Inc Actuals & Estimates (NASDAQ:RLMD) - TradingView
RLMD Forecast — Price Target — Prediction for 2027 - TradingView
4E2 Forecast — Price Target — Prediction for 2027 - TradingView
Relmada Therapeutics (RLMD) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Relmada Therapeutics Inc (RLMD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Relmada Therapeutics Inc (NASDAQ: RLMD) Share Price, RLMD Stock News, RLMD Share Price & Updates - Kalkine
Relmada Therapeutics stock maintained at Buy by H.C. Wainwright - Investing.com
H.C. Wainwright Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $12 - Moomoo
H.C. Wainwright Reiterates Buy Rating on Relmada Therapeutics Inc (RLMD) - StreetInsider
Form 13G Relmada Therapeutics For: 22 June By Investing.com - Investing.com Australia
Millennium Group reports 4.57M Relmada shares (NASDAQ: RLMD) in 13G - Stock Titan
RLMD Q1 2026 Earnings: Wider-than-Expected Loss Amid Ongoing Clinical DevelopmentMargin Guidance - dars.gov.et
Relmada Therapeutics, Inc.(NasdaqCM:RLMD) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Relmada: NDV-01 Entering Phase 3 In NMIBC, But There's No Rush To Buy Stock Today - Seeking Alpha
Relmada Therapeutics Inc (RLMD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Relmada Therapeutics (RLMD): 10 Best Growth Stocks Under $30 to Buy Now - Insider Monkey
RLMD News | RELMADA THERAPEUTICS INC (NASDAQ:RLMD) - ChartMill
RLMD Initiates Coverage On by HC Wainwright & Co. -- Rating Set to Buy - GuruFocus
Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call - Benzinga
H.C. Wainwright initiates Relmada stock coverage with buy rating By Investing.com - Investing.com South Africa
H.C. Wainwright initiates Relmada stock coverage with buy rating - Investing.com
H.C. Wainwright Initiates Relmada Therapeutics(RLMD.US) With Buy Rating, Announces Target Price $12 - Moomoo
H.C. Wainwright Starts Relmada Therapeutics Inc (RLMD) at Buy, PT $12 - StreetInsider
10 Best Growth Stocks Under $30 to Buy Now - Insider Monkey
Relmada Therapeutics Inc (RLMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Relmada Therapeutics Inc (RLMD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Relmada Therapeutics Inc (RLMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Relmada Therapeutics Inc Stock (RLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Relmada Therapeutics Inc Stock (RLMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shenouda Maged | Chief Financial Officer |
Dec 15 '25 |
Buy |
4.12 |
11,665 |
48,060 |
800,000 |
| Shenouda Maged | Chief Financial Officer |
Nov 05 '25 |
Buy |
2.20 |
500,000 |
1,100,000 |
788,335 |
| Ence Chuck | CAO and COO |
Nov 05 '25 |
Buy |
2.20 |
136,000 |
299,200 |
403,931 |
| TRAVERSA SERGIO | Chief Executive Officer |
Nov 05 '25 |
Buy |
2.20 |
272,500 |
599,500 |
1,272,500 |
| Kelly Paul Edward | Chief Operating Officer |
Nov 05 '25 |
Buy |
2.20 |
90,000 |
198,000 |
502,295 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 27 '25 |
Buy |
0.67 |
129,455 |
86,735 |
944,024 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 26 '25 |
Buy |
0.62 |
80,545 |
49,938 |
814,569 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 28 '25 |
Buy |
0.74 |
55,976 |
41,422 |
1,000,000 |
1.40%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):